论文部分内容阅读
目的 观察急性冠脉综合征的早期应用辛伐他汀后C反应蛋白和血脂的变化。方法 70例急性冠脉综合征患者随机分为对照组(无服用任何调脂药物,34例)和治疗组(辛伐他汀10mg/d ,36例) ,测定治疗前后C反应蛋白和血脂的变化。结果 治疗组治疗5d后C反应蛋白水平下降35 % ,与治疗前比较差异有显著意义(P <0 . 0 5 ) ;治疗4周后TC、LDL C分别下降30 %、4 0 % ,与治疗前比较差异有显著意义;而且随访期间治疗组的心肌梗死发生率、再住院率均明显低于对照组。结论 在急性冠脉综合征早期予以辛伐他汀治疗是可行及有效的,可明显降低血脂和血浆炎症因子的水平,可能有利于动脉粥样斑块的稳定。
Objective To observe the changes of C-reactive protein and lipids in early stage of acute coronary syndrome after simvastatin. Methods Seventy patients with acute coronary syndrome were randomly divided into control group (without any lipid-lowering drugs, 34 cases) and treatment group (simvastatin 10 mg / d, 36 cases). The changes of C-reactive protein and serum lipid . Results After treatment for 5 days, the level of C-reactive protein in the treatment group decreased by 35%, which was significantly different from that before treatment (P <0.05). After 4 weeks of treatment, TC and LDL C decreased by 30% and 40% respectively, Before the difference was significant; and during follow-up of the treatment group, the incidence of myocardial infarction, rehospitalization were significantly lower than the control group. Conclusions It is feasible and effective to take simvastatin in the early stage of acute coronary syndrome. It can significantly reduce the levels of blood lipids and plasma inflammatory cytokines and may be beneficial to the stability of atherosclerotic plaques.